Art. -Nr.: HY-101923

LYN-1604

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.47%
CAS. Nr.: 2088939-99-3
Formel: C₃₃H₄₃Cl₂N₃O₂
Molecular Weight:584.62

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

LYN-1604 Chemical Structure

CAS. Nr.: 2088939-99-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC)^[1].

IC₅₀ & Target^[1]

ULK1

18.94 nM (EC₅₀)

Alle ULK Isoform-spezifische Produkte anzeigen :

ULK1
ULK2

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC₅₀	1.66 μM Compound: 8; LYN-1604	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 29509411]
MDA-MB-231	IC₅₀	1.66 μM Compound: 12; LYN-1604	Antiproliferative activity against human MDA-MB-231 cells assessed reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37595546]
MDA-MB-231	IC₅₀	1.66 μM Compound: LYN-1604	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 38432059]

In Vitro

LYN-1604 is a potential ULK1 agonist (enzymatic activity=195.7% at 100 nM and IC₅₀=1.66 μM against MDA-MB-231 cells) ^[1].
LYN-1604 binds to wild-type ULK1 with a binding affinity in the nanomole range (K_D=291.4 nM) ^[1].
LYN-1604 (0.5, 1.0 and 2.0 μM) induces cell death via the ULK complex in MDA-MB-231 cells^[1].
LYN-1604 (0.5-2 μM, 24 hours) induces remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II in MDA-MB-231 cells^[1].
LYN-1604 induces ATG5-dependent autophagy via the ULK complex^[1].
LYN-1604 can also increase cleavage of caspase3 and induce apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MDA-MB-231 cells
Concentration:

0.5, 1.0 and 2.0 μM
Incubation Time:
Result:

Induced cell death. Autophagy ratio was increased in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231 cells
Concentration:

0, 0.5, 1, and 2 μM
Incubation Time:

24 hours
Result:

Induced remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II.

In Vivo

LYN-1604 (low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg; intragastric administration once a day for 14 days) inhibits the growth of xenograft TNBC by targeting ULK1-modulated cell death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

24 female nude mice (BALB/c, 6-8 weeks, 20-22 g)^[1]
Dosage:

Low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg
Administration:

Intragastric administration; once a day for 14 days
Result:

Significantly inhibited the growth of xenograft MDA-MB-231 cells. The body weights of mice were stable. By the end of the experiment, the liver and spleen weight indexes of mice were slightly increased in parts of the groups, while the kidney weight index was not affected in all dose groups.

Chemical Information

CAS. Nr. 2088939-99-3
Appearance Oil
Molecular Weight 584.62
Formel C₃₃H₄₃Cl₂N₃O₂
Color Colorless to light yellow
SMILES

ClC1=CC=C(C(CN2CCN(C(CN(CC(C)C)CC(C)C)=O)CC2)OCC3=CC=C(C=CC=C4)C4=C3)C(Cl)=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (7)

All WBIF

Sort by:

Journal Impact Factor

Nat Aging

Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology. [Abstract]

2026 May 14. PMID: 42135576
J Transl Med

Pbk positively regulates myoblast differentiation and muscle regeneration via enhancing AMPK/ULK1 mediated myogenic autophagy. [Abstract]

2025 Oct 21;23(1):1144. PMID: 41121382

LYN-1604 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Oct 21;23(1):1144. [Abstract]

C2C12 cells treated with or without HI-TOPK-032 (2 μM) and LYN-1604 (2 μM) were induced to differentiation for 3 days. After that, cells were harvested and subjected to western blot to detect and quantify the protein levels of MyHC and autophagy related genes.

LYN-1604 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Oct 21;23(1):1144. [Abstract]

C2C12 cells treated with or without HI-TOPK-032 (2 μM) and LYN-1604 (2 μM) were induced to differentiation for 3 days. Then cells were fixed and stained for MyHC (green) and DAPI (blue) to detect and quantify the differentiation index and fusion index of differentiating C2C12 cells.
Antioxidants (Basel)

Hyperosmolarity-Induced Oxidative Stress Leads to Senescence in Human Corneal Epithelial Cells (HCEPC) via DNA Damage, Metabolic Disturbance and Mitophagy Decline. [Abstract]

2025 Nov 19;14(11):1381. PMID: 41300537
Med Oncol

ULK1-driven autophagy modulation alters tumor-promoting pathways in triple-negative breast cancer. [Abstract]

2026 Mar 3;43(4):163. PMID: 41774346
Cell Signal

microRNA-125b-1-3p mediates autophagy via the RRAGD/mTOR/ULK1 signaling pathway and mitigates atherosclerosis progression. [Abstract]

2024 Jun:118:111136. PMID: 38471617
Biochem J

Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2). [Abstract]

2019 Mar 12;476(5):875-887. PMID: 30782972
Oxid Med Cell Longev

ULK1 Suppresses Osteoclast Differentiation and Bone Resorption via Inhibiting Syk-JNK through DOK3. [Abstract]

2021 Nov 15:2021:2896674. PMID: 34820053

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (171.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7105 mL

8.5526 mL

17.1051 mL

5 mM

0.3421 mL

1.7105 mL

3.4210 mL

10 mM

0.1711 mL

0.8553 mL

1.7105 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang L, et al. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci. 2017 Apr 1;8(4):2687-2701. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7105 mL	8.5526 mL	17.1051 mL	42.7628 mL
	5 mM	0.3421 mL	1.7105 mL	3.4210 mL	8.5526 mL
	10 mM	0.1711 mL	0.8553 mL	1.7105 mL	4.2763 mL
	15 mM	0.1140 mL	0.5702 mL	1.1403 mL	2.8509 mL
	20 mM	0.0855 mL	0.4276 mL	0.8553 mL	2.1381 mL
	25 mM	0.0684 mL	0.3421 mL	0.6842 mL	1.7105 mL
	30 mM	0.0570 mL	0.2851 mL	0.5702 mL	1.4254 mL
	40 mM	0.0428 mL	0.2138 mL	0.4276 mL	1.0691 mL
	50 mM	0.0342 mL	0.1711 mL	0.3421 mL	0.8553 mL
	60 mM	0.0285 mL	0.1425 mL	0.2851 mL	0.7127 mL
	80 mM	0.0214 mL	0.1069 mL	0.2138 mL	0.5345 mL
	100 mM	0.0171 mL	0.0855 mL	0.1711 mL	0.4276 mL

Keywords

LYN-1604

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LYN-1604

Apoptosis Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Breast Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) LYN-1604

Alle ULK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LYN-1604

Apoptosis Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Breast Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) LYN-1604

Alle ULK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LYN-1604 Related Classifications

HY-101923 Related Classifications